Do firms respond to peer disclosures? Evidence from clinical trial disclosures
We examine whether a firm’s decision to disclose non-financial proprietary information depends on peer disclosures of similar information. Using a sample of 5,035 unique clinical trials by U.S. pharmaceutical firms over the 2007-2014 period, we find that the firm is less likely to disclose its own c...
Saved in:
Main Authors: | CAPKUN, Vedran, LOU, Yun, OTTO, Clemens A., WANG, Yin |
---|---|
Format: | text |
Language: | English |
Published: |
Institutional Knowledge at Singapore Management University
2021
|
Subjects: | |
Online Access: | https://ink.library.smu.edu.sg/soa_research/1789 https://ink.library.smu.edu.sg/context/soa_research/article/2816/viewcontent/SSRN_id3344942otto.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Singapore Management University |
Language: | English |
Similar Items
-
Do firms respond to peer disclosures? Evidence from disclosures of clinical trial results
by: CAPKUN, Vedran, et al.
Published: (2023) -
Consequences of disclosing clinical trial results: Evidence from the food and drug administration amendments act
by: BORVEAU, Thomas, et al.
Published: (2020) -
The effect of mandatory ESG disclosure on firms’ going-private decisions
by: HUANG, Ying-Chi
Published: (2024) -
Regulatory interventions in response to noncompliance with mandatory derivatives disclosure rules
by: BHATTACHARYA, Neil, et al.
Published: (2022) -
Trade secrets law and corporate disclosure: Causal evidence on the proprietary cost hypothesis
by: LI, Yinghua, et al.
Published: (2018)